Stanley Druckenmiller and 25 Other Big Funds Sold Thermo Fisher Scientific Last Quarter, While 15 Bought. Who’s Right?
26 large funds, including Stanley Druckenmiller's Duquesne, sold Thermo Fisher Scientific (TMO) last quarter, while 15 bought. Viking Global sold $687M, Lone Pine bought $673M. Thermo Fisher raised 2026 outlook, and Danaher's guidance suggests improving demand. Analysts' average price target is achievable through earnings growth alone. Danaher (DHR) serves similar customers, potentially indicating market trends.
How this was made
The 30-second read
Why it matters
Fund activity of this magnitude can influence short‑term price dynamics and inform traders about institutional sentiment.
Market read
Large fund moves in a mega‑cap biotech equipment company provide actionable insight for short‑term traders.
What to watch
Thermo Fisher's recent 2026 outlook raise and Danaher’s guidance may offset fund sell signals.
Background
The article summarizes 13F filings for the quarter ended Sept. 30, 2026, highlighting fund turnover in Thermo Fisher Scientific (TMO).
Ticker impact
13F filings show several large funds sold Thermo Fisher while others bought, indicating mixed sentiment and potential near‑term volatility.
potential volatility with pressure from sellers and support from buyers; direction unclear
The article provides the first public disclosure of sizable fund trades ($687M sold, $673M bought) that can move the stock.
Market effects
Thermo Fisher's biotech and lab‑equipment sector may see heightened attention as fund flows signal valuation debate.
U.S. investors may adjust exposure to the broader life‑sciences space.
Limited to investors tracking large‑cap biotech equipment stocks.
Counterpoint
The sizable buy side (Lone Pine, Castle Hook) could indicate undervaluation despite recent sell pressure.
Key entities
- companyThermo Fisher Scientific
Life‑sciences equipment maker (ticker TMO).

